IDH2 and central nervous system cancer: As in the original presentation of Uromonitor®, where multiple molecular targets are evaluated simultaneously, for gliomas, TERTmonitor can be expanded to include other biomarkers as IDH or targeting other events as the common hotspot mutations in pediatric settings, e.g., H3F3A and BRAF hotspots, as previously suggested by other authors [42].